Comparative Pharmacology
Head-to-head clinical analysis: DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE versus Q PAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE versus Q PAM.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE vs Q-PAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.
Q-PAM is a quaternary ammonium neuromuscular blocking agent that competitively blocks acetylcholine at nicotinic receptors at the neuromuscular junction, causing depolarizing neuromuscular blockade.
One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.
100 mg orally twice daily
None Documented
None Documented
Dutasteride: Terminal half-life ~5 weeks (3-7 weeks), allowing once-daily dosing; steady-state reached at 3-6 months. Tamsulosin: Terminal half-life ~9-13 hours in healthy subjects, prolonged in elderly (up to 16-19 hours).
Terminal half-life: 8-12 hours (mean 10 h) in healthy adults. Prolonged in renal impairment (up to 24 h in CrCl <30 mL/min); no dose adjustment needed in mild-moderate hepatic impairment.
Dutasteride: 40% as metabolites in feces (mainly via bile), 5% in urine. Tamsulosin: 76% in urine as unchanged drug and metabolites, 24% in feces.
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total clearance ~12 L/h.
Category A/B
Category C
Alpha-1 Blocker
Alpha-1 Blocker